Clinical Trial Update: International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi [Phase 4]

View source ↗

Summary

Phase 4 international multicenter trial evaluating immunogenicity of GamEvac-Combi (Ebola vaccine) completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• GamEvac-Combi

Snippet

Sponsor: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Conditions: Ebola Virus Disease, Prevention | Phase 4 | Status: COMPLETED